Literature DB >> 11514003

Contralateral breast cancer risk.

J Unnithan1, R M Macklis.   

Abstract

The use of breast-conserving treatment approaches for breast cancer has now become a standard option for early stage disease. Numerous randomized studies have shown medical equivalence when mastectomy is compared to lumpectomy followed by radiotherapy for the local management of this common problem. With an increased emphasis on patient involvement in the therapeutic decision making process, it is important to identify and quantify any unforeseen risks of the conservation approach. One concern that has been raised is the question of radiation- related contralateral breast cancer after breast radiotherapy. Although most studies do not show statistically significant evidence that patients treated with breast radiotherapy are at increased risk of developing contralateral breast cancer when compared to control groups treated with mastectomy alone, there are clear data showing the amount of scattered radiation absorbed by the contralateral breast during a routine course of breast radiotherapy is considerable (several Gy) and is therefore within the range where one might be concerned about radiogenic contralateral tumors. While radiation related risks of contralateral breast cancer appear to be small enough to be statistically insignificant for the majority of patients, there may exist a smaller subset which, for genetic or environmental reasons, is at special risk for scatter related second tumors. If such a group could be predicted, it would seem appropriate to offer either special counseling or special prevention procedures aimed at mitigating this second tumor risk. The use of genetic testing, detailed analysis of breast cancer family history, and the identification of patients who acquired their first breast cancer at a very early age may all be candidate screening procedures useful in identifying such at- risk groups. Since some risk mitigation strategies are convenient and easy to utilize, it makes sense to follow the classic 'ALARA' (as low as reasonably achievable) principles and to minimize scattered radiation for these special risk groups and perhaps for all patients undergoing breast radiotherapy. This paper reviews the literature on the risk of radiation- related second contralateral breast cancers.

Entities:  

Mesh:

Year:  2001        PMID: 11514003     DOI: 10.1016/s0167-8140(01)00369-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Assessment of contralateral mammary gland dose in the treatment of breast cancer using accelerated hypofractionated radiotherapy.

Authors:  Maria Tolia; Kalliopi Platoni; Andreas Foteineas; Maria-Aggeliki Kalogeridi; Anna Zygogianni; Nikolaos Tsoukalas; Mariangela Caimi; Niki Margari; Maria Dilvoi; Panagiotis Pantelakos; John Kouvaris; Vassilis Kouloulias
Journal:  World J Radiol       Date:  2011-09-28

2.  Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum.

Authors:  M Uhl; F Sterzing; G Habl; K Schubert; H Holger; J Debus; K Herfarth
Journal:  Strahlenther Onkol       Date:  2012-01-06       Impact factor: 3.621

3.  Characterization of a novel scale maille contralateral breast shield: SMART Armor.

Authors:  Macinley Butson; Susan Carroll; Martin Butson; Robin Hill
Journal:  J Appl Clin Med Phys       Date:  2017-08-11       Impact factor: 2.102

4.  Dosimetric comparison of intensity modulated radiotherapy isocentric field plans and field in field (FIF) forward plans in the treatment of breast cancer.

Authors:  Zakiya Salem Al-Rahbi; Zahid Al Mandhari; Ramamoorthy Ravichandran; Fatma Al-Kindi; Cheriyathmanjiyil Anthony Davis; Saju Bhasi; Namrata Satyapal; Balakrishnan Rajan
Journal:  J Med Phys       Date:  2013-01

5.  Stromal PTEN determines mammary epithelial response to radiotherapy.

Authors:  Gina M Sizemore; Subhasree Balakrishnan; Katie A Thies; Anisha M Hammer; Steven T Sizemore; Anthony J Trimboli; Maria C Cuitiño; Sarah A Steck; Gary Tozbikian; Raleigh D Kladney; Neelam Shinde; Manjusri Das; Dongju Park; Sarmila Majumder; Shiva Krishnan; Lianbo Yu; Soledad A Fernandez; Arnab Chakravarti; Peter G Shields; Julia R White; Lisa D Yee; Thomas J Rosol; Thomas Ludwig; Morag Park; Gustavo Leone; Michael C Ostrowski
Journal:  Nat Commun       Date:  2018-07-17       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.